augmentin hcg

This is a summary of a preprint research study by Zhi-Lu Wang and colleagues from The First Hospital of Lanzhou University on Research Square, provided to you by Medscape. This study has not yet been peer-reviewed. The full text of the study can be found on Researchsquare.com.

Key Takeaway

• Patients with coronary artery disease (CAD) who received anti-inflammatory therapy had significantly lower incidence of cardiovascular death, myocardial infarction (MI), and stroke than patients not receiving anti-inflammatory therapy, discount lipitor 80mg results of a systematic review and meta-analysis of randomized trials suggest.  

Why This Matters

• Chronic inflammation and its association with the development of atherosclerosis and CAD has been hypothesized for many years; however, the efficacy of anti-inflammatory therapy has remained controversial and is not currently recommended by the guidelines in patients with CAD.

Study Design

• Researchers used data from randomized controlled trials including 61,164 patients with CAD (32,227 patients receiving anti-inflammatory therapy and 28,937 not receiving anti-inflammatory therapy).

• Anti-inflammatory therapies included colchicine, PLA₂ inhibitors such as varespladib and darapladib, as well as canakinumab and methotrexate.

• The primary outcome was a composite of cardiovascular death, MI, and stroke. Secondary outcomes included MI, coronary revascularization, cardiovascular death, all-cause death, and stroke.

Key Results

• The primary outcome was significantly lower in patients receiving anti-inflammatory therapy than those who did not (10.66% vs 10.86%; relative risk [RR] 0.93; 95% CI, 0.89 – 0.98; P = .006).

• Anti-inflammatory therapy was associated with a significantly reduced risk of MI compared with patients not receiving anti-inflammatory therapy (5.66% vs 6.03%; RR, 0.90; 95% CI, 0.84 – 0.96; P = .002).

• Coronary revascularization was significantly lower in patients taking anti-inflammatory therapy (1.94% vs 2.66%; RR, 0.74; 95% CI, 0.66 – 0.84; P < .00001).

• There was no statistical difference in the risk of cardiovascular death, all-cause death, and stroke between groups.

• Anti-inflammatory drugs targeting the central interleukin-6 inflammatory signaling pathway such as colchicine and canakinumab reduced the risk of primary outcome but anti-inflammatory therapy using PLA₂ inhibitors showed no statistically significant effect.  

Limitations

• Participants in this trial included patients with acute coronary syndrome and chronic coronary syndrome, potentially causing heterogeneity.

• The three small-sample-size trials had a low incidence of positive events and a wide confidence interval, reducing the quality of evidence.

• Low follow-up rate of three trials reduces the reliability of results.

Study Disclosures

• No disclosures

For more from theheart.org | Medscape Cardiology, join us on Twitter and Facebook

Source: Read Full Article